(TheNewswire)
LONDON, ONTARIO - TheNewswire - November 30,2020 - Sernova Corp. (TSXV:SVA) (OTC:SEOVF ) (FSE:PSH), a leading clinical-stage regenerative medicinetherapeutics company, is pleased to announce that Dr. Piotr Witkowski,principal investigator in Sernova's ongoing Phase I/II clinical trial, A Safety, Tolerability and EfficacyStudy of Sernova's Cell Pouch(TM) for Clinical IsletTransplantation will present data and observations from thetrial in an oral presentation delivered at the American Society ofTransplant Surgeons 21 st Annual State of the Art Winter Symposium.
Dr. Witkowski, Director, Pancreatic and Islet Transplant Program atthe University of Chicago, is scheduled to deliver his presentation, IsletAllotransplantation Into Pre-Vascularized Sernova CellPouch (TM) -Preliminary Results From The University of Chicago, to morethan 600 transplant professionals as part of the Oral Abstract SessionII on January 15, 2021 at 2:05 PM. Further details on the program andregistration can be found on ASTS Winter Symposium website ( https://asts.org/events-meetings/winter-symposium )
ABOUT ASTS AND THE 21 st ANNUAL STATE OF THE ART WINTER SYMPOSIUM
The American Society of Transplant Surgeons represents approximately1,900 professionals dedicated to excellence in transplantationsurgery. ASTS advances the art and science of transplant surgerythrough patient care, research, education, and advocacy.
ASTS 21st Annual State of the Art Winter Symposium will be heldvirtually January 14 - 16, 2021.
Beginning on January 14, the sessions will be available virtually todisseminate the latest science in transplantation surgery.
ABOUT SERNOVA'S CLINICAL TRIAL
Sernova is conducting a Phase I/II non-randomized, unblinded,single-arm, company-sponsored trial to assess the safety andtolerability of islet transplantation into the company's patented CellPouch in diabetic subjects with hypoglycemia unawareness. The primaryobjective of the study is to assess the safety of the Cell Pouchfollowing implantation and transplantation. The secondary objective isto assess efficacy through a series of defined measures. Patientsenrolled in Sernova's clinical trial are incapable of producingC-peptide, a biomarker for insulin produced by islet cells.
Eligible subjects are implanted with Cell Pouches. Following thedevelopment of vascularized tissue chambers within the Cell Pouch,subjects are then stabilized on immunosuppression, and a dose ofpurified islets, under strict release criteria, is transplanted intothe Cell Pouch.
A sentinel pouch is removed for an early assessment of the islettransplant. Subjects are followed for additional safety and efficacymeasures for approximately six months. At this point, a decision willbe made with regards to the transplant of a second islet dose withsubsequent safety and efficacy follow-up. Patients will be thenfurther followed for one year to assess longer-term safety andefficacy.
For more information on the clinical trial, please visit www.clinicaltrials.gov/ct2/show/NCT03513939 .
For more information on enrollment and recruitment details pleasevisit www.pwitkowski.org/sernova .
ABOUT SERNOVA CORP.
Sernova Corp is developing regenerative medicine therapeutictechnologies using a medical device and immune protected therapeuticcells (i.e. human donor cells, corrected human cells, and stemcell-derived cells) to improve the treatment and quality of life ofpeople with chronic metabolic diseases such as insulin-dependentdiabetes, blood disorders including hemophilia, and other diseasestreated through replacement of proteins or hormones missing or inshort supply within the body. For more information, please visit www.sernova.com
For further information contact:
Dominic Gray
Sernova Corp
Tel: (519) 858-5126
Copyright (c) 2020 TheNewswire - All rights reserved.